These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

510 related items for PubMed ID: 18312543

  • 1. Effect of tolterodine on gastrointestinal transit and bowel habits in healthy subjects.
    Bharucha AE, Seide B, Guan Z, Andrews CN, Zinsmeister AR.
    Neurogastroenterol Motil; 2008 Jun; 20(6):643-8. PubMed ID: 18312543
    [Abstract] [Full Text] [Related]

  • 2. Comparison of selective M3 and nonselective muscarinic receptor antagonists on gastrointestinal transit and bowel habits in humans.
    Bharucha AE, Ravi K, Zinsmeister AR.
    Am J Physiol Gastrointest Liver Physiol; 2010 Jul; 299(1):G215-9. PubMed ID: 20395537
    [Abstract] [Full Text] [Related]

  • 3. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome.
    Andresen V, Camilleri M, Busciglio IA, Grudell A, Burton D, McKinzie S, Foxx-Orenstein A, Kurtz CB, Sharma V, Johnston JM, Currie MG, Zinsmeister AR.
    Gastroenterology; 2007 Sep; 133(3):761-8. PubMed ID: 17854590
    [Abstract] [Full Text] [Related]

  • 4. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome.
    Robinson D, Cardozo L, Terpstra G, Bolodeoku J, Tamsulosin Study Group.
    BJU Int; 2007 Oct; 100(4):840-5. PubMed ID: 17822465
    [Abstract] [Full Text] [Related]

  • 5. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR, Van Kerrebroeck PE, Jünemann KP, Wang JT, Brodsky M.
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
    Chapple C, Herschorn S, Abrams P, Sun F, Brodsky M, Guan Z.
    Eur Urol; 2009 Sep; 56(3):534-41. PubMed ID: 19070418
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA, Roehrborn CG, Chancellor M, Carlsson M, Bavendam T, Guan Z.
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [Abstract] [Full Text] [Related]

  • 10. Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants > or = 50 years.
    Olshansky B, Ebinger U, Brum J, Egermark M, Viegas A, Rekeda L.
    J Cardiovasc Pharmacol Ther; 2008 Dec; 13(4):241-51. PubMed ID: 18832343
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
    Rogers RG, Bachmann G, Scarpero H, Jumadilova Z, Sun F, Morrow JD, Guan Z, Bavendam T.
    Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
    [Abstract] [Full Text] [Related]

  • 13. Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder.
    Rovner ES, Rackley R, Nitti VW, Wang JT, Guan Z, 037 Study Group.
    Urology; 2008 Sep; 72(3):488-93. PubMed ID: 18639327
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome.
    Tseng LH, Wang AC, Chang YL, Soong YK, Lloyd LK, Ko YJ.
    Neurourol Urodyn; 2009 Sep; 28(1):47-51. PubMed ID: 19089890
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Evaluation of an experimental urodynamic platform to identify treatment effects: a randomized, placebo-controlled, crossover study in patients with overactive bladder.
    Frenkl T, Railkar R, Shore N, Bailen J, Sutherland S, Burke J, Scott BB, Ruddy M, Beals C.
    Neurourol Urodyn; 2012 Jan; 31(1):69-74. PubMed ID: 21905086
    [Abstract] [Full Text] [Related]

  • 18. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.
    Abrams P, Kaplan S, De Koning Gans HJ, Millard R.
    J Urol; 2006 Mar; 175(3 Pt 1):999-1004; discussion 1004. PubMed ID: 16469601
    [Abstract] [Full Text] [Related]

  • 19. The clinical efficacy of tolterodine extended-release is maintained for 24 h in patients with overactive bladder.
    Dmochowski R, Kreder K, MacDiarmid S, Carlsson M, Guan Z.
    BJU Int; 2007 Jul; 100(1):107-10. PubMed ID: 17552957
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.